Genetic Aspects of Alzheimer Disease

Author(s):

Derek van Amerongen, MD, MS,Soeren Mattke, MD, DSc

The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.

EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease

Now Viewing

EP: 3.Genetic Aspects of Alzheimer Disease

EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease

EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing

EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 9.Clinical Decision-Making for Alzheimer Disease Management

EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease

EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease

EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

[Dr Snider] Discuss the genetic factors associated with AD. How do mutations in genes such as APP, PSEN1, and PSEN2 contribute to the pathophysiology of the disease? How do different alleles of APOE4affect risk of developing AD?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!